Compare Abeona Therapeutics Inc (ABEO) vs Synchrony Financial (SYF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Synchrony Financial — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Synchrony Financial trades at $72.01 (market cap $25.40B). The key difference: Synchrony Financial is far larger — about 68× Abeona Therapeutics Inc's market cap, and Synchrony Financial pays a 1.59% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | SYF | |
|---|---|---|
Market Cap | $373.32M | $25.40B |
Sector | Health | Financials |
52-Week High | $7.23 | $88.47 |
52-Week Low | $4.17 | $63.78 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SYF trades at $77.05, up 0.94% today, with a bullish technical outlook supported by moving averages and key resistance at $78. The stock shows strong fundamentals with a P/E of 7.98, net income margin of 24.06%, and consistent earnings beats in recent quarters. Recent news highlights executive changes and partnership expansions, reinforcing growth initiatives.
The outlook remains positive with a consensus price target of $85, representing ~10% upside. Risks include interest rate sensitivity and competitive pressures, but strong analyst buy ratings (62.5%) and robust cash flow support a favorable investment case for value-oriented investors seeking financial sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
